Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Shares Issued (2021 - 2025)

Aligos Therapeutics' Shares Issued history spans 5 years, with the latest figure at $124000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 10.79% year-over-year to $124000.0; the TTM value through Dec 2025 reached $263000.0, up 187.96%, while the annual FY2025 figure was $304000.0, 30.28% down from the prior year.
  • Shares Issued reached $124000.0 in Q4 2025 per ALGS's latest filing, down from $139000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $720000.0 in Q4 2021 to a low of -$438000.0 in Q3 2023.
  • Average Shares Issued over 5 years is $118307.7, with a median of $101000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: tumbled 605.56% in 2022, then surged 333.66% in 2023.
  • A 5-year view of Shares Issued shows it stood at $720000.0 in 2021, then tumbled by 74.31% to $185000.0 in 2022, then crashed by 336.76% to -$438000.0 in 2023, then soared by 131.74% to $139000.0 in 2024, then fell by 10.79% to $124000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Shares Issued are $124000.0 (Q4 2025), $139000.0 (Q4 2024), and -$438000.0 (Q3 2023).